Nurix Therapeutics Inc. (NASDAQ:NRIX) shares traded 4.02% higher at $12.69 on Wall Street last session.
In accordance with the data, 11 analysts cover Nurix Therapeutics Inc. (NASDAQ:NRIX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $53.00 and a low of $11.00, we find $35.00. Given the previous closing price of $12.20, this indicates a potential upside of 186.89 percent. NRIX stock price is now 6.11% away from the 50-day moving average and -2.28% away from the 200-day moving average. The market capitalization of the company currently stands at $575.24M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
It has been rated a hold by 1 analysts and a buy by 9. Brokers who have rated the stock have averaged $34.09 as their price target over the next twelve months.
With the price target of $11, Morgan Stanley recently initiated with Equal-Weight rating for Nurix Therapeutics Inc. (NASDAQ: NRIX). On May 31, 2022, Wells Fargo Upgraded its previous ‘Equal Weight’ rating to ‘Overweight’ on the stock keeping its target price maintained at $25, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, Wolff Stefani, EVP and COO sold 350 shares of the company’s stock on Oct 31. The stock was sold for $4,508 at an average price of $12.88. Upon completion of the transaction, the EVP and COO now directly owns 3,402 shares in the company, valued at $43171.38. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 31, Chief Scientific Officer Hansen Gwenn sold 1,165 shares of the business’s stock. A total of $15,006 was realized by selling the stock at an average price of $12.88. This leaves the insider owning 21,214 shares of the company worth $0.27 million. Insiders disposed of 8,744 shares of company stock worth roughly $0.11 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NRIX stock. A new stake in Nurix Therapeutics Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $12,594,000. CITADEL ADVISORS LLC invested $1,760,000 in shares of NRIX during the first quarter. In the first quarter, BNP PARIBAS ARBITRAGE, SNC acquired a new stake in Nurix Therapeutics Inc. valued at approximately $970,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in NRIX for approximately $963,000. D. E. SHAW & CO., INC. purchased a new stake in NRIX valued at around $762,000 in the second quarter. In total, there are 182 active investors with 94.40% ownership of the company’s stock.
Nurix Therapeutics Inc. (NASDAQ: NRIX) opened at $12.46 on Friday. During the past 12 months, Nurix Therapeutics Inc. has had a low of $7.52 and a high of $20.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.30, and a quick ratio of 5.30. The fifty day moving average price for NRIX is $11.95 and a two-hundred day moving average price translates $12.98 for the stock.
The latest earnings results from Nurix Therapeutics Inc. (NASDAQ: NRIX) was released for Aug, 2022. According to the Biotechnology Company, earnings per share came in at -$0.9, beating analysts’ expectations of -$0.98 by 0.08. This compares to -$0.65 EPS in the same period last year. The company reported revenue of $10.79 million for the quarter, compared to $10.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.26 percent. For the current quarter, analysts expect NRIX to generate $17.17M in revenue.
Nurix Therapeutics Inc.(NRIX) Company Profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
